Donation

Resource
The IMF’s Patient Handbook simplifies the daunting disease. It provides an overview of myeloma, with a focus on getting the correct diagnosis, the tests you really need, initial treatment options, and supportive care and how to get it.
October 25, 2018
Resource
Helpful to health professionals and patients alike, the IMF’s Concise Review provides an in-depth overview of myeloma, with a discussion of the epidemiology, pathophysiology, clinical features, treatment options, and new and emerging treatments.
October 25, 2018
Resource
The Understanding series of cancer information booklets clearly and easily explain multiple myeloma treatments and care. Free for download.
October 25, 2018
Resource
Designed to serve as consistent references in a concise manner, the IMF’s Tip Cards cover key topics, including treatment and care issues of interest to patients and caregivers.
October 25, 2018
Resource
This glossary defines commonly used myeloma-related terms.-As of April 19, 2021Accrual: The process of enrolling patients in a clinical trial (research study), or the number of patients already enrolled in a trial or anticipated to enroll in a trial.Acute:…
November 21, 2019
Resource
A reference list of common acronyms and abbreviations that are used in myeloma.
October 25, 2018
Resource
This tool tracks drugs from discovery to development to FDA approval for myeloma.
October 25, 2018
Resource
We’ve partnered with Smart Patients, an online community where patients and caregivers affected by complex illness learn from each other about treatments, challenges, and how it all fits into the context of their experience.
October 25, 2018
Resource
Myeloma Manager™ provides a tool to capture laboratory results and display and print tables and charts to show how those results change over time. Other features include automatic backup of your data each time you shut down the program, calendars, and graph features such as plotting multiple tests…
October 25, 2018
Resource
This multicenter IMWG study identifies relapsed multiple myeloma patients who: have received at least three prior lines of therapy, are refractory to both an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI), and have been exposed to an alkylating…
May 12, 2017
Resource
These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including: A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002…
October 03, 2003
Resource
Do you want to receive the latest myeloma news and research for free, directly in your email inbox? You can with the Myeloma Minute! Subscribe below to receive weekly email newsletters with up-to-the 'minute' information about multiple myeloma. The Myeloma Minute includes: …
September 19, 2018
Resource
Because multiple myeloma presents as clinically and biologically heterogeneous, treatment and response outcomes vary. Because treatment options have increased and will continue to do so, there must be a way to better understand the heterogeneity of the disease and apply this understanding to…
February 28, 2014
Resource
This study provides the most current information for patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. It aims to aid clinicians to ensure that patients with myeloma receive the most appropriate care in everyday clinical practice. The study finds that…
February 20, 2014
Resource
Even though the landscape for multiple myeloma diagnosis and management has substantially developed in the past 10 years, the clinical guidelines that provide recommendations on standard treatment for myeloma patients does not take into account the limitations of resources in developing countries.…
November 14, 2013
Resource
Now more than ever before, multiple myeloma patients are assessed and treated more precisely. New technologies are now able to “evaluate the biology and extent of the disease,” including the following: cytogenetic information genetic abnormalities extramedullary…
June 23, 2013
Resource
This study seeks to “assess the independent contributions of International Staging System (ISS) stage and cytogenetic abnormalities in predicting outcomes. This international effort used the International Myeloma Working Group database of 12,137 patients treated worldwide for myeloma at diagnosis,…
March 27, 2013
Resource
Plasma cell leukemia (PCL), a rare and aggressive variant of myeloma, is characterized by the presence of circulating plasma cells. It is classified as either: primary PCL occurring at diagnosis, or secondary PCL in patients with relapsed/refractory myeloma. …
January 04, 2013
Resource
Peripheral neuropathy (PN), a complication of multiple myeloma (MM) treatment, can be caused by the myeloma itself, other aspects of the disease, or by its treatment. Such causes include the effects of the monoclonal protein, the results of radiculopathy from direct…
April 26, 2012
Resource
Many new drugs show promise in the treatment of multiple myeloma (MM); however, their “impact should be measured against the expected outcome in patients failing current therapies.” This study focused on “286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following,…
January 26, 2012
Resource
It is important to maintain the results of induction therapy in multiple myeloma patients. The International Myeloma Working Group reviewed data associated with induction therapy. Learn more about these induction treatments that were studied. The IMWG concluded that when deciding on treatment…
January 23, 2012
Resource
As novel agents are being more commonly used for the treatment of multiple myeloma, the role of high-dose therapy followed by autologous stem cell transplantation (ASCT) continues to evolve. Induction therapy is no longer just conventional chemotherapy regimens. Rather, induction therapy now uses “…
March 29, 2011
Resource
This study sought to “identify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN).” Analyzed were 1,495 patients with multiple myeloma. The clinicians learned that “an individual’s risk of developing a peripheral neuropathy after…
March 01, 2011
Resource
Many cancer patients who undergo chemotherapy experience peripheral neuropathy, which is characterized by numbness, tingling, and/or pain in the hands, feet, legs, and/or arms. In fact, almost every effective regimen for the treatment of multiple myeloma “includes at least one agent that can cause…
March 01, 2011
Resource
This analysis focuses on comparing both early onset and late onset bortezomib-induced peripheral neuropathy to vincristine-induced peripheral neuropathy. When a myeloma patient has dose-limiting based toxicity due to bortezomib, bortezomib-induced peripheral neuropathy may result, negatively…
November 11, 2010
Resource
This report from the International Myeloma Working Group (IMWG) focuses on the multiple myeloma (MM) and its complication of lytic bone disease. Lytic bone disease is a disease that destroys the bone and can rarely be reversed. To observe lytic bone disease’s impact, “biochemical markers of bone…
October 24, 2010
Resource
This statement concludes that treating multiple myeloma (MM) patients with allogeneic stem-cell transplantation (Allo-SCT) is not more successful than autologous stem-cell transplantation. In addition, more guidelines are needed to be set in order to make Allo-SCT a better form of treatment.…
October 10, 2010
Resource
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21,463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom’s macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is…
June 24, 2010
Resource
The purpose of this study is to determine the correlation between age and survival, as well as how many years myeloma patients will lose due to their condition. In the study, 10,549 patients were studied, with 6,996 receiving conventional therapy, and 3,553 patients receiving high-dose therapy with…
March 20, 2010
Resource
Bone disease in myeloma occurs as a result of complex interactions between myeloma cells and the bone marrow microenvironment. A custom-built DNA single nucleotide polymorphism (SNP) chip containing 3404 SNPs was used to test genomic DNA from myeloma patients classified by the extent of bone…
October 23, 2009
Resource
This booklet is focused on therapies given to patients with myeloma bone involvement. Bisphosphonate therapy is not treatment for myeloma, but it does help to prevent skeletal complications of myeloma. Monoclonal antibody therapy targets a protein which controls bone regeneration and remodeling.
June 06, 2019
Resource
The International Myeloma Working Group (IMWG) provides a statement on autologous stem cell support (ASCT). This statement explains how multiple myeloma calls for high-dose chemotherapy with ASCT most commonly in North America as of present. Generally, this is executed by collecting at least 2…
October 23, 2009
Resource
The goals of this paper are the following: to biologically classify multiple myeloma “based on known genetic subtypes with associated clinico-pathological associations” “to establish the prognostic value of known and new genetic factors for MM outcome, including the…
October 01, 2009
Resource
The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important…
August 27, 2009
Resource
This statement reviews imaging methods that can detect bone and soft tissue damage caused by multiple myeloma (MM), including the following: Conventional radiography: “gold standard” in imaging studies of myeloma patients Computed tomography (CT): When an MRI is not…
May 07, 2009
Resource
When treating myeloma patients with thalidomide, there is a possible risk of venous thromboembolism that can follow with a risk of pulmonary embolism. “To test genetic variation associated with treatment related VTE in patient peripheral blood DNA,” this study uses a “custom-built molecular…
December 15, 2008
Resource
This statement attempts to explain four aspects of myeloma: 20,000 new American patients are diagnosed every year There are about 100,000 myeloma patients in America due to better forms of treatment that increase survival rates. This statistic is the same throughout Europe…
August 22, 2008
Resource
Not much information has been obtained on multiple myeloma’s (MM) occurrence rates and treatments in Latin America. However, this analysis observes factors of MM in Brazil based on information provided by sixteen institutions. This study identified “the unique aspect of the pattern of the disease…
May 03, 2008
Resource
This analysis compares 1689 multiple myeloma patients under the age of 50 with 8860 patients at least 50 years old or older. Distinguishing factors from the younger group were that myeloma was more common among men, had a low International Staging System (ISS) stage, had a low Durie-Salmon stage,…
April 15, 2008
Resource
This manuscript intends to explain prophylaxis strategies for venous thromboembolism (VTE). VTE is more common in cancer patients than in the general population, whose VTE occurrence is more than 1 in every thousand. In the context of multiple myeloma patients, their risk of VTE increases when…
February 22, 2008
Resource
This statement made by the International Myeloma Working Group (IMWG) responds to the Mayo Clinic’s statement on using bisphosphonates (BPs) on patients with multiple myeloma. The Mayo Clinic is usually in agreement with the IMWG. However, in this instance, the IMWG does not entirely agree with the…
April 04, 2007
Resource
The methods to consider when analyzing the outcomes of myeloma clinical trials have been expanded in the European Group for Blood and Bone Marrow Transplant/ International Bone Marrow Transplant Registry. This revised form of International Response Criteria may possibly be widely used in future…
July 20, 2006
Resource
This research focuses on unifying a multiple myeloma staging system around the world called the International Staging System (ISS). Information was taken from 10,750 myeloma patients previously untreated from North America, Asia, and Europe. The results of testing three different assessments for…
May 20, 2005
Resource
As treatment for myeloma improves and patients live longer, it is important to reduce the disability that can result from the painful problem of vertebral compression fractures, which occur when the vertebra collapses or fractures because the bone is too weak to withstand the pressure or stress…
May 18, 2019
Resource
Protecting yourself and your medical information
January 18, 2019
Resource
Dear Reader A message from IMF President Susie Durie Scientific & Clinical ASCENT Trial to Treat High-Risk Smoldering Multiple Myeloma Launching Across the US Nurse Leadership Board…
December 18, 2018
Resource
Dear Reader A message from IMF President Susie Novis Scientific & Clinical Highlights of the 2018 Annual Meeting of the American Society of Clinical Oncology Highlights of the 2018 Summit of the…
September 04, 2018
Resource
Dear Reader A message from IMF President Susie Novis Scientific & Clinical Immunotherapy…
April 30, 2018
Resource
  Dear Reader A message from IMF President Susie Novis Scientific & Clinical 2018 IMF Brian D. Novis Research Grants Highlights of the 2017 Annual Meeting of the American Society of Hematology…
February 13, 2018
Resource
Dear Reader A message from IMF President Susie Novis Scientific & Clinical Darzalex in Frontline Therapy Clinical Trial Kyprolis in Relapsed/Refractory Myeloma Sixth Annual Master Class for…
November 16, 2017

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.